Sartorius Invests in Nanotein to Boost Cell Therapy Tools

Sartorius Stedim Biotech, a collaborator with the biopharmaceutical industry, has entered into a collaboration with Nanotein Technologies, a developer of immune cell activation reagents. Sartorius Stedim Biotech intends to invest up to $3 million for a minority stake in Nanotein for the commercialization and joint development of solutions based on the Nanotein NanoSpark platform.

Sartorius Stedim Biotech will offer Nanotein’s leading products globally, the NanoSpark STEM-T Soluble T Cell Activator and NanoSpark GROW-NK Soluble Activator, under an exclusive distribution agreement. These reagents are designed to enhance the yield and expansion of T cells and natural killer (NK) cells for use in cellular therapies and modern technologies, including CAR-T and NK cell-based cancer treatments.

Also Read: Imugene and NeoImmuneTech Sign Pact To Improve Cancer Treatments

Cell therapy manufacture starts with the activation of immune cells to produce large numbers of high-quality cells, but developers are countered with a few challenges, such as reliance on feeder cells and variability of yield. “Nanotein’s soluble activators aim to address these challenges by enhancing cell expansion and providing a feeder-free solution for NK cell activation,” said Curtis Hodge, Co-Founder and CEO of Nanotein Technologies.

The partnership would give clients access to technologies that streamline processes and enhance the production of immune cells to promote innovation, from early development to clinical use, said René Fáber, CEO of Sartorius Stedim Biotech.